[Federal Register Volume 78, Number 250 (Monday, December 30, 2013)]
[Notices]
[Pages 79465-79469]
[FR Doc No: 2013-31212]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-1676]

International Drug Scheduling; Convention on Psychotropic
Substances; Single Convention on Narcotic Drugs; Tapentadol; Tramadol;
Ketamine; gamma-Butyrolactone; 22 Additional Substances; Request for
Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is requesting

interested persons to submit comments concerning abuse potential,
actual abuse, medical usefulness, trafficking, and impact of scheduling
changes on availability for medical use of 26 drug substances. These
comments will be considered in preparing a response from the United
States to the World Health Organization (WHO) regarding the abuse
liability and diversion of these drugs. WHO will use this information
to consider whether to recommend that certain international
restrictions be placed on these drugs. This notice requesting comments
is required by the Controlled Substances Act (CSA).

DATES: Submit written or electronic comments by January 29, 2014.

ADDRESSES: Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.regulations.gov.

FOR FURTHER INFORMATION CONTACT: James R. Hunter, Center for Drug
Evaluation and Research, Controlled Substance Staff, Food and Drug
Administration, Bldg. 51, Rm. 5150, 10903 New Hampshire Ave., Silver
Spring, MD 20993-0002,<PHONE_NUMBER>, email<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: The United States is a party to the 1971
Convention on Psychotropic Substances. Article 2 of the Convention on
Psychotropic Substances provides that if a party to the convention or
WHO has information about a substance, which in its opinion may require
international control or change in such control, it shall so notify the
Secretary General of the United Nations and provide the Secretary
General of the United Nations with information in support of its
opinion.
    Section 201 of the CSA (21 U.S.C. 801 et seq.) (Title II of the
Comprehensive Drug Abuse Prevention and Control Act of 1970) provides
that when WHO notifies the United States under Article 2 of the
Convention on Psychotropic Substances that it has information that may
justify adding a drug or other substances to one of the schedules of
the convention, transferring a drug or substance from one schedule to
another, or deleting it from the schedules, the Secretary of State must
transmit the notice to the Secretary of Health and Human Services (the
Secretary of HHS). The Secretary of HHS must then publish the notice in
the Federal Register and provide opportunity for interested persons to
submit comments that will be considered by HHS in its preparation of
the scientific and medical evaluations of the drug or substance.

I. WHO Notification

    The Secretary of HHS received the following notices from WHO:

Ref.: C.L.29.2013

    The World Health Organization (WHO) presents its compliments to
Member States and Associate Members and has the pleasure of
informing that the Thirty-sixth Expert Committee on Drug Dependence
(ECDD) will meet in June 2014 to review a number of substances with
potential for misuse in order to make recommendations to the
Director-General, on the need for and level of international control
of these substances.
    At its 126th session in January 2010, the Executive Board
approved the publication ``Guidance on the WHO review of
psychoactive substances for international control'' (EB126/2010/
REC1, Annex 6) which requires the Secretariat to request relevant
information from Ministers of Health in Member States to prepare a
report for submission to the ECDD. For this purpose, a questionnaire
was designed to gather information on the legitimate use, harmful
use, status of national control and potential impact of
international control for each substance under evaluation. Member
States are invited to collaborate, as in the past, in this process
by providing pertinent information mentioned in the questionnaire
concerning substances under review.
    It would be appreciated if a person from the Ministry of Health
could be designated as the focal point responsible for coordinating
and answering the questionnaire. It is requested that the email
address of the focal point be shared with the Secretariat * * *.
Upon receipt of the email of the designated person, the focal point
will receive a unique user name, password and link for accessing the
questionnaire and responding to questions. Further instructions on
answering the questionnaire will be provided, along with the
questionnaire, online. Further clarification on the above items can
be obtained from the Secretariat by emailing<EMAIL_ADDRESS>Replies to the questionnaire must reach the
Secretariat by 1 February 2014 in order to facilitate analyses and
preparation of the report before the planned meeting. Where there is
a Competent National Authority under the International Drug Control
Treaties, it is kindly requested that the questionnaire be completed
in collaboration with such body. The summary information from the
questionnaire will be published online as part of the report at the
Web site for the Thirty-sixth ECDD linked to the Department of
Essential Medicines and Health Products (EMP): http://www.who.int/medicines/areas/quality_safety/ECDD/en/index.html.
    The World Health Organization takes this opportunity to renew to
Member States and Associate Members the assurance of its highest
consideration.

    GENEVA, 11 November 2013
* * * * *
ENCL.: (1)

Substances Identified for Evaluation During the 36th Expert Committee
on Drug Dependence

Tapentadol
N-benzylpiperazine (BZP)
Gamma-Butyrolactone (GBL)
1,4-Butanediol (I,4BD)
Synthetic cannabinoids
    JWH-018
    JWH-073
    AM-2201
    UR-144
    APINACA (AKB 48)
    RCS-4
    JWH-250

Synthetic Cathinones
    Mephedrone 4-methylmethcathinone (4-MMC)
    3,4-Methylenedioxypyrovalerone (MDPV)
    Methylone (bk-MDMA)
    4-Methylethcathinone (4-MEC)
    4-Fluoromethcathinone (flephedrone; 4-FMC)
Miscellaneous
    25 B NBOMe
    25 C NBOMe
    25 I NBOMe
    Alpha-methyltryptamine (AMT)
    AH-7921
    Methoxetamine (MXE)
    Methiopropamine (MPA)
Lisdexamphetamine
Tramadol
Ketamine

* * * * *

WHO Questionnaire for the 36th Meeting of Expert Committee on Drug
Dependence: Substance

Definitions:

    (Def. 1) Legitimate use is use of a substance for legally valid
purposes such as medical scientific and industrial.
    (Def. 2) Harmful use is defined as a pattern of psychoactive
substance use that increases the risk of harmful physical, mental,
and social consequences for the user or to others. Harmful use of
drugs by an individual has potential for adverse effects on the
substance user's family, the community and society in general.

Substance* (Insert name of substance)

--Do you have any information on this substance on legitimate use,
recreational/harmful use or control status in your country? \*\
(Yes/No)

A. LEGITIMATE MEDICAL OR OTHER SCIENTIFIC USE OF THE SUBSTANCE (Def. 1)

--Is the substance currently authorized or in the process of being
authorized/registered as a medical product in your country? (Yes/No)

    If ``yes,'' since when has it been on the market? (input year)

--Please state registered indications for this medicine:
--Please mention other, if any, medical use not included in the
approved indications (off label use):
--Please indicate dosage form(s) and strength(s) available in your
country; also

indicate special properties such as slow release, etc.:

------------------------------------------------------------------------
                      Dosage form         Strength           Remarks
------------------------------------------------------------------------
1.                 .................  ................  ................
2.                 .................  ................  ................
3.                 .................  ................  ................
------------------------------------------------------------------------

--Please list alphabetically the brand names available in your
country (there is no need for dosage forms, strengths, etc.):
--Are there any other uses for the substance in health care (such as
for diagnostic tests) in your country? (Yes/No)
    If ``yes,'' what is the use?
--Is the chemical used for medical or scientific research in your
country? (Yes/No)
    If ``yes,'' please specify:
--Is the substance used for animal care (veterinary use)? (Yes/No)
--Is there any other legitimate (Def. 1) use of the substance (e.g.
industry uses)? (Yes/No)
    If ``yes,'' please state the purpose:
--If there is any legitimate (Def. 1) use of the substance, how is
the substance sourced? (Manufactured in country/Imported)
--What is the estimated approximate amount needed for its legitimate
use in your country per year?
--Is the substance used for cultural or ceremonial purposes? (Yes/
No)
    If ``yes,'' specify why it is used:
    Who uses it (the group using)?
    How is it used? (route of administration):
    What is its source?

B. HARMFUL USE OF THE SUBSTANCE (Def. 2)

--Is there recreational/harmful use of this substance in your
country? (Def. 2) (Yes/No/Unknown)
    If ``yes,'' please specify how the substance is used and the
extent of use by answering the following questions:
    Common route(s) of administration (Oral/Injection/Inhaling or
sniffing)
    How is it obtained? (Diversion/Trafficking/Clandestine
manufacturing)
    Common formulation(s) available: (Powder/Tablet/Liquid)

--Any other information on recreational/harmful use:
--Quantity of substance used by an average misuse per sitting
(average dose used):
--Is it used by special population(s)? (Club use/General population)

------------------------------------------------------------------------
                                                            General
                                         Club use          population
                                        (percent)          (percent)
------------------------------------------------------------------------
Estimated proportion of the
 population using the substance...
------------------------------------------------------------------------

--Please provide any information on the extent/magnitude of public
health or social harm from the use of the substance (Def. 2) in your
country:

----------------------------------------------------------------------------------------------------------------
                                                             Addiction
                                                             programme        Emergency room
                                       Overdose deaths     enrolment from    visits resulting    Dependence to
                                           reported       the use of this    from the use of     this substance
                                                             substance        this substance
----------------------------------------------------------------------------------------------------------------
Numbers in 2012.....................
----------------------------------------------------------------------------------------------------------------

--Are there reports of withdrawal, tolerance, other adverse effects
or medical illnesses caused by this substance in your country? (Yes/
No)
    If ``yes,'' please provide details:
--Any other relevant information on harm to individuals or the
society:
--Please indicate the sources of information on harm:
--If actual data are not available, please provide a short
description on harm caused by this substance:

C. CONTROL OF THE SUBSTANCE

--Is the substance controlled under legislation that is intended to
regulate its availability in the country? (Yes/No)

    If ``yes,'' please select which one: (Controlled substances act/
Medicines law/Poisons acts/Consumer protection acts/Generic
legislation/Analogue legislation/Temporary ban/Other legislation
(name))

--How is this law enforced? Please provide a short description:
--Are there challenges to implementation? (Yes/No)

    If ``yes,'' please specify (e.g. laboratory capacity, resources
to implement and/or enforce, expertise):

--Are there illicit activities involving the substance? (Yes/No)
    Clandestine manufacture? (Yes/No)
    The manufacture (synthesis) of the chemical itself (Yes/No)
    The processing into the consumer product, i.e. adding it to
herbal material, packaging (Yes/No)
    Trafficking (Yes/No)
    Diversion (Yes/No)
    Internet market (Yes/No)
    Other (please specify):
--Please provide any other relevant information on illicit
activities:
--Data on seizures

--------------------------------------------------------------------------------------------------------------------------------------------------------
                                            Number of                                                Number of      Number of tablets/     Other type
                 Year                        seizures          Kilograms            Litres            ampoules            pills            (quantity)
--------------------------------------------------------------------------------------------------------------------------------------------------------
2011..................................
2012..................................
--------------------------------------------------------------------------------------------------------------------------------------------------------

D. IMPACT OF SCHEDULING

--If this substance is placed under international control, does your
country have the lab capacity to identify the substance? (Yes/No/
Unknown)
--If this substance is placed under international control, do you
think its availability for medical use will be affected? (Yes/No)

    If ``yes,'' please explain (consider both human and veterinary
needs): How could control impact its medical availability? Please
identify specific population groups that may be affected, and
describe the implications of increased control.

--Any additional information on impact of scheduling:
* * * * *

II. Background

    Tapentadol is a central nervous system active analgesic agent that
has mu ([micro]) opioid agonist properties and inhibits the reuptake of
norepinephrine. Tapentadol is approved for marketing in the United
States for the treatment of moderate to severe acute pain.

Tapentadol is controlled in Schedule II under the CSA in the United
States. Tapentadol was pre-reviewed by the WHO Expert Committee on Drug
Dependence at its 35th meeting and recommended for critical review at
its 36th meeting.
    N-benzylpiperazine (BZP) is used as an intermediate in chemical
synthesis but has been taken orally as either powder or tablets and by
other routes, including smoking or snorting. It has no medical use in
the United States. BZP is controlled in Schedule I under the CSA in the
United States. BZP is not controlled internationally under the
Convention on Psychotropic Substances or the Single Convention on
Narcotic Drugs. BZP was pre-reviewed by the WHO Expert Committee on
Drug Dependence at its 35th meeting and recommended for critical review
at its 36th meeting.
    Gamma-Butyrolactone (GBL) is used as an industrial solvent. GBL can
be converted in the body to the central nervous system depressant drug
gamma-hydroxybutyric acid (GHB). GBL is controlled as a List I chemical
in the United States under the CSA. It is not controlled
internationally under the Convention on Psychotropic Substances or the
Single Convention on Narcotic Drugs. GBL was pre-reviewed by the WHO
Expert Committee on Drug Dependence at its 35th meeting and recommended
for critical review at its 36th meeting.
    1,4-Butanediol is used as an industrial solvent for manufacturing
and also used for the synthesis of GBL. 1,4-Butanediol can also be
converted to the central nervous depressant drug GHB. It has no medical
use in the United States. 1,4-Butanediol is not controlled under the
CSA in the United States, but it is subject to controls in several
states under state law. 1,4-Butanediol was pre-reviewed by the WHO
Expert Committee on Drug Dependence at its 35th meeting and recommended
for critical review at its 36th meeting.
    The following substances are classified as synthetic cannabinoids
with pharmacological properties like tetrahydrocannabinol: (1-pentyl-
1H-indol-3-yl)-1-naphthalenyl-methanone (JWH-018), (1-butyl-1H-indol-3-
yl)-1-naphthalenyl-methanone (JWH-073), 1-(1-pentyl-1H-indol-3-yl)-2-
(2-methoxyphenyl)-ethanone (JWH-250), [1-(5-fluoropentyl)-1H-indol-3-
yl]-1-naphthalenyl-methanone (AM-2201), (1-pentyl-1H-indol-3-
yl)(2,2,3,3-tetramethylcyclopropyl)-methanone (UR-144), 1-pentyl-N-
tricyclo[<IP_ADDRESS>,7]dec-l-yl-1H-indazole-3-carboxamide (APINACA;
AKB48), and (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone (RCS-4).
JWH-018, JWH-073, JWH-250, AM-2201, and RCS-4 are controlled in
Schedule I under the CSA in the United States. On May 16, 2013, UR-144
and AKB 48 were temporarily placed in Schedule I under the CSA pursuant
to the temporary scheduling provisions of section 201(h) of the CSA (21
U.S.C. 811(h)).
    4-Methylmethcathinone (4-MMC; mephedrone), 3,4-
methylenedioxypyrovalerone (MDPV), 3,4-methylenedioxy-N-methylcathinone
(bk-MDMA; Methylone), 4-methylethcathinone (4-MEC), and 4-
fluoromethcathinone (flephedrone; 4-FMC) are classified as synthetic
cathinones in the phenethylamine class and are structurally and
pharmacologically similar to amphetamine, 3,4-
methylenedioxymethamphetamine (MDMA), cathinone and other related
substances. 4-MMC, MDPV, and Methylone are controlled in Schedule I
under the CSA in the United States. 4-MEC and 4-FMC are not controlled
under the CSA in the United States.
    2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-
methoxyphenyl)methyl]ethanamine (25B-NBOMe), 2-(4-chloro-2,5-
dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe), and 2-(4-
iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-
NBOMe) are synthetic 2C phenethylamine substances and were developed
for use in mapping and investigating the serotonin receptors in the
mammalian brain. On November 15, 2013, 25B-NBOMe, 25C-NBOMe, and 25I-
NBOMe were temporarily placed in Schedule I of the CSA pursuant to the
temporary scheduling provision of section 201(h) of the CSA.
    Alpha-Methyltryptamine (AMT) is a tryptamine (indoleethylamine)
derivative and shares several similarities with the Schedule I
tryptamine hallucinogens, such as alpha-ethyltryptamine (AET) and N,N-
dimethyltryptamine (DMT). AMT is controlled in Schedule I under the CSA
in the United States.
    AH-7921, or 1-(3,4-dichlorobenzamidomethyl)cyclohexyldimethylamine,
is an opioid analgesic drug selective for the [micro]-opioid receptor
and is not controlled under the CSA in the United States.
    Methoxetamine (MXE), or 2-(ethylamino)-2-(3-methoxyphenyl)-
cyclohexanone, is an arylcyclohexamine and is not controlled under the
CSA in the United States. MXE can be considered as a controlled
substance analogue of eticyclidine (PCE) under the CSA if intended for
human consumption.
    Methiopropamine (MPA) is a thiophene analog of methamphetamine and
is not controlled under the CSA in the United States.
    Lisdexamphetamine is an amide ester conjugate comprised of the
amino acid L-lysine covalently bound to the amino group of d-
amphetamine. Lisdexamphetamine was approved for marketing in the United
States in 2007 and is used for the treatment of Attention Deficit
Hyperactivity Disorder. Lisdexamphetamine was placed in Schedule II of
the CSA in June 2007.
    Tramadol is an opioid analgesic that produces its primary opioid-
like action through an active metabolite referred to as the M1
metabolite[middot](O-desmethyltramadol). Tramadol was first approved
for marketing in the United States in 1995 and is available in
immediate-release, extended-release, and combination product for the
treatment of moderate to moderately-severe pain. In November 2013,
Tramadol was proposed to be placed in Schedule IV of the CSA. The
Secretariat indicates that additional safety information on this
substance is available, thus an updated review for Tramadol is
necessary for presentation at the 36th meeting of the WHO Expert
Committee on Drug Dependence.
    Ketamine is classified as a rapid-acting general anesthetic agent
used for short diagnostic and surgical procedures that do not require
skeletal muscle relaxation. It is marketed in the United States as an
injectable. Ketamine is controlled in Schedule III of the CSA in the
United States. It is not controlled internationally under the
Convention on Psychotropic Substances or the Single Convention on
Narcotic Drugs. The WHO Expert Committee on Drug Dependence reviewed
ketamine at its 34th and 35th meetings. The Secretariat indicates that
additional safety information on this substance is available, thus an
updated review for ketamine is necessary for presentation at the 36th
meeting of the WHO Expert Committee on Drug Dependence.

III. Opportunity To Submit Domestic Information

    As required by section 201(d)(2)(A) of the CSA, FDA, on behalf of
the Department of Health and Human Services (HHS), invites interested
persons to submit comments regarding the 26 named drugs. Any comments
received will be considered by HHS when it prepares a scientific and
medical evaluation of these drugs. HHS will forward a scientific and
medical

evaluation of these drugs to WHO, through the Secretary of State, for
WHO's consideration in deciding whether to recommend international
control/decontrol of any of these drugs. Such control could limit,
among other things, the manufacture and distribution (import/export) of
these drugs and could impose certain recordkeeping requirements on
them.
    HHS will not now make any recommendations to WHO regarding whether
any of these drugs should be subjected to international controls.
Instead, HHS will defer such consideration until WHO has made official
recommendations to the Commission on Narcotic Drugs, which are expected
to be made in early 2015. Any HHS position regarding international
control of these drugs will be preceded by another Federal Register
notice soliciting public comments, as required by section 201(d)(2)(B)
of the CSA.

IV. Comments

    Interested persons may submit either electronic comments regarding
the drugs to http://www.regulations.gov or written comments to the
Division of Dockets Management (see ADDRESSES) by January 29, 2014. It
is only necessary to send one set of comments. Identify comments with
the docket number found in brackets in the heading of this notice.
Received comments may be seen in the Division of Dockets Management
between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to
the docket at http://www.regulations.gov.

    Dated: December 24, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-31212 Filed 12-27-13; 8:45 am]
BILLING CODE 4160-01-P


[Federal Register Volume 85, Number 66 (Monday, April 6, 2020)]
[Notices]
[Page 19217]
[FR Doc No: 2020-07118]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Motor Carrier Safety Administration

[Docket No. FMCSA-2015-0327; FMCSA-2016-0003; FMCSA-2017-0057]

Qualification of Drivers; Exemption Applications; Hearing

AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.

ACTION: Notice of final disposition.

-----------------------------------------------------------------------

SUMMARY: FMCSA announces its decision to renew exemptions for 14
individuals from the hearing requirement in the Federal Motor Carrier
Safety Regulations (FMCSRs) for interstate commercial motor vehicle
(CMV) drivers. The exemptions enable these hard of hearing and deaf
individuals to continue to operate CMVs in interstate commerce.

DATES: Each group of renewed exemptions were applicable on the dates
stated in the discussions below and will expire on the dates provided
below.

FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief,
Medical Programs Division,<PHONE_NUMBER><EMAIL_ADDRESS>FMCSA,
Department of Transportation, 1200 New Jersey Avenue SE, Room W64-224,
Washington, DC 20590-0001. Office hours are from 8:30 a.m. to 5 p.m.,
ET, Monday through Friday, except Federal holidays. If you have
questions regarding viewing or submitting material to the docket,
contact Docket Operations,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Public Participation

A. Viewing Documents and Comments

    To view comments, as well as any documents mentioned in this notice
as being available in the docket, go to http://www.regulations.gov/docket?D=FMCSA-2015-0327 or http://www.regulations.gov/docket?D=FMCSA-2016-0003 or http://www.regulations.gov/docket?D=FMCSA-2017-0057 and
choose the document to review. If you do not have access to the
internet, you may view the docket online by visiting the Docket
Operations in Room W12-140 on the ground floor of the DOT West
Building, 1200 New Jersey Avenue SE, Washington, DC 20590, between 9
a.m. and 5 p.m., ET, Monday through Friday, except Federal holidays.

B. Privacy Act

    In accordance with 5 U.S.C. 553(c), DOT solicits comments from the
public to better inform its rulemaking process. DOT posts these
comments, without edit, including any personal information the
commenter provides, to www.regulations.gov, as described in the system
of records notice (DOT/ALL-14 FDMS), which can be reviewed at
www.transportation.gov/privacy.

II. Background

    On February 6, 2020, FMCSA published a notice announcing its
decision to renew exemptions for 14 individuals from the hearing
standard in 49 CFR 391.41(b)(11) to operate a CMV in interstate
commerce and requested comments from the public (85 FR 6999). The
public comment period ended on March 9, 2020, and no comments were
received.
    FMCSA has evaluated the eligibility of these applicants and
determined that renewing these exemptions would achieve a level of
safety equivalent to, or greater than, the level that would be achieved
by complying with Sec.  391.41(b)(11).
    The physical qualification standard for drivers regarding hearing
found in Sec.  391.41(b)(11) states that a person is physically
qualified to drive a CMV if that person first perceives a forced
whispered voice in the better ear at not less than 5 feet with or
without the use of a hearing aid or, if tested by use of an audiometric
device, does not have an average hearing loss in the better ear greater
than 40 decibels at 500 Hz, 1,000 Hz, and 2,000 Hz with or without a
hearing aid when the audiometric device is calibrated to American
National Standard (formerly ASA Standard) Z24.5--1951.
    This standard was adopted in 1970 and was revised in 1971 to allow
drivers to be qualified under this standard while wearing a hearing
aid, 35 FR 6458, 6463 (April 22, 1970) and 36 FR 12857 (July 3, 1971).

III. Discussion of Comments

    FMCSA received no comments in this proceeding.

IV. Conclusion

    Based upon its evaluation of the 14 renewal exemption applications,
FMCSA announces its decision to exempt the following drivers from the
hearing requirement in Sec.  391.41 (b)(11).
    As of February 24, 2020, and in accordance with 49 U.S.C. 31136(e)
and 31315(b), Yoel Perez (FL) has satisfied the renewal conditions for
obtaining an exemption from the hearing requirement in the FMCSRs for
interstate CMV drivers. (85 FR 6999)
    This driver was included in docket number FMCSA-2015-0327. The
exemption is applicable as of February 24, 2020, and will expire on
February 24, 2022.
    As of February 19, 2020, and in accordance with 49 U.S.C. 31136(e)
and 31315(b), the following 13 individuals have satisfied the renewal
conditions for obtaining an exemption from the hearing requirement in
the FMCSRs for interstate CMV drivers (85 FR 6999):

Wyatt Baldwin (NV)
Marion Bennett, Jr. (MD)
Richard Davis (OH)
Adam Hayes (CA)
Michael Lidster (IL)
Adrian Lopez (TX)
Michael Quinonez (NM)
Khon Saysanam (TX)
Jeffrey Schulkers (KY)
Jason Thomas (TX)
Roderick Thomas (GA)
Joshua Tinley (AZ)
Kerri Wright (OK)

    The drivers were included in docket number FMCSA-2016-0003 or
FMCSA-2017-0057. Their exemptions are applicable as of February 19,
2020, and will expire on February 19, 2022.
    In accordance with 49 U.S.C. 31315(b), each exemption will be valid
for 2 years from the effective date unless revoked earlier by FMCSA.
The exemption will be revoked if the following occurs: (1) The person
fails to comply with the terms and conditions of the exemption; (2) the
exemption has resulted in a lower level of safety than was maintained
prior to being granted; or (3) continuation of the exemption would not
be consistent with the goals and objectives of 49 U.S.C. 31136(e) and
31315(b).

Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2020-07118 Filed 4-3-20; 8:45 am]
 BILLING CODE 4910-EX-P